BE2013C035I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2013C035I2 BE2013C035I2 BE2013C035C BE2013C035C BE2013C035I2 BE 2013C035 I2 BE2013C035 I2 BE 2013C035I2 BE 2013C035 C BE2013C035 C BE 2013C035C BE 2013C035 C BE2013C035 C BE 2013C035C BE 2013C035 I2 BE2013C035 I2 BE 2013C035I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301129 | 2003-08-05 | ||
| US49545103P | 2003-08-14 | 2003-08-14 | |
| EP04739008A EP1660531A2 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2013C035I2 true BE2013C035I2 (enExample) | 2023-12-14 |
Family
ID=34117520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C035C BE2013C035I2 (enExample) | 2003-08-05 | 2013-06-11 | |
| BE2013C038C BE2013C038I2 (enExample) | 2003-08-05 | 2013-06-19 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C038C BE2013C038I2 (enExample) | 2003-08-05 | 2013-06-19 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7615532B2 (enExample) |
| EP (3) | EP2264065B1 (enExample) |
| JP (1) | JP4463814B2 (enExample) |
| KR (1) | KR101159559B1 (enExample) |
| AU (2) | AU2004261353B2 (enExample) |
| BE (2) | BE2013C035I2 (enExample) |
| BR (1) | BRPI0413276B8 (enExample) |
| CA (1) | CA2531988C (enExample) |
| CY (5) | CY1113850T1 (enExample) |
| FR (2) | FR13C0035I2 (enExample) |
| HU (1) | HUS1300033I1 (enExample) |
| IL (1) | IL172980A (enExample) |
| LU (2) | LU92213I2 (enExample) |
| MX (1) | MXPA06001283A (enExample) |
| NO (5) | NO340925B1 (enExample) |
| PL (1) | PL2107069T3 (enExample) |
| RU (1) | RU2518460C2 (enExample) |
| WO (1) | WO2005012347A2 (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1648933T1 (sl) * | 2003-07-25 | 2010-01-29 | Conjuchem Biotechnologies Inc | Dolgo delujoäś inzulinski derivat in metoda zanj |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| EP2256130B1 (en) * | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| JP5410020B2 (ja) | 2005-02-02 | 2014-02-05 | ノヴォ ノルディスク アー／エス | インスリン誘導体 |
| US20090074882A1 (en) * | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| DE602007009496D1 (de) | 2006-02-27 | 2010-11-11 | Novo Nordisk As | Insulinderivate |
| WO2007104736A2 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| US8293965B2 (en) | 2006-04-28 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Antimicrobial site dressings |
| US8796205B2 (en) | 2006-05-09 | 2014-08-05 | Novo Nordisk A/S | Insulin derivative |
| CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| EP2015770B1 (en) * | 2006-05-09 | 2012-09-26 | Novo Nordisk A/S | Insulin derivative |
| JP5097900B2 (ja) * | 2006-06-27 | 2012-12-12 | 独立行政法人物質・材料研究機構 | 有機酸又はこれらの誘導体の活性エステル体の製造方法 |
| EP2049149B1 (en) | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Pegylated extended insulins |
| EP2404934A1 (en) | 2006-09-22 | 2012-01-11 | Novo Nordisk A/S | Protease resistant insulin analogues |
| ES2563038T3 (es) | 2007-04-30 | 2016-03-10 | Novo Nordisk A/S | Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca |
| US20100190706A1 (en) * | 2007-06-01 | 2010-07-29 | Novo Nordisk A/S | Stable Non-Aqueous Pharmaceutical Compositions |
| EP2164466A1 (en) | 2007-06-01 | 2010-03-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| KR20100053561A (ko) | 2007-08-15 | 2010-05-20 | 노보 노르디스크 에이/에스 | 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체 |
| CN101784563B (zh) | 2007-08-15 | 2015-02-04 | 诺沃-诺迪斯克有限公司 | 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素 |
| CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
| WO2009060071A1 (en) * | 2007-11-08 | 2009-05-14 | Novo Nordisk A/S | Insulin derivative |
| ES2612736T3 (es) | 2007-11-16 | 2017-05-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| ES2618073T3 (es) | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| CN106317164A (zh) | 2008-09-12 | 2017-01-11 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| CA2738615A1 (en) * | 2008-10-30 | 2010-05-06 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| ES2692495T3 (es) | 2009-01-23 | 2018-12-03 | Novo Nordisk A/S | Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos |
| CN102666579A (zh) | 2009-10-30 | 2012-09-12 | 诺沃—诺迪斯克有限公司 | 降钙素基因相关肽的衍生物 |
| CN102753150A (zh) * | 2010-01-12 | 2012-10-24 | 诺沃—诺迪斯克有限公司 | 用于口服给予胰岛素肽的药物组合物 |
| JP5826772B2 (ja) | 2010-02-16 | 2015-12-02 | ノヴォ ノルディスク アー／エス | コンジュゲートタンパク質 |
| ES2582590T3 (es) | 2010-02-16 | 2016-09-13 | Novo Nordisk A/S | Método de purificación |
| EP2569002B1 (en) | 2010-05-10 | 2016-10-26 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| EP2576588A4 (en) | 2010-05-25 | 2014-07-09 | Syngene Ltd | METHODS FOR SYNTHESIZING DICARBA BRIDGES CONTAINING ALKYNES IN PEPTIDES |
| EP2585484A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| EP2585483A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Human insulin containing additional disulfide bonds |
| WO2011161125A1 (en) | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| EP2627670A2 (en) | 2010-10-15 | 2013-08-21 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
| JP6049625B2 (ja) * | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| SI2632478T1 (sl) | 2010-10-27 | 2019-11-29 | Novo Nordisk As | Zdravljenje sladkorne bolezni z uporabo inzulinskih injekcij, ki se dajejo v različnih injicirnih intervalih |
| US20130331320A1 (en) | 2010-12-14 | 2013-12-12 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
| US20140011728A1 (en) | 2011-02-15 | 2014-01-09 | Novo Nordisk A/S | Long-acting il-1 receptor antagonists |
| KR20140020292A (ko) * | 2011-03-28 | 2014-02-18 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
| EP2696847A1 (en) | 2011-04-14 | 2014-02-19 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| CN103596584B (zh) | 2011-06-15 | 2016-12-14 | 诺沃—诺迪斯克有限公司 | 多取代的胰岛素 |
| JP6352806B2 (ja) * | 2011-09-23 | 2018-07-04 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| EP2784085A4 (en) * | 2011-12-15 | 2015-07-08 | Shanghai Hengrui Pharm Co Ltd | HUMAN INSULIN ANALOG AND ACYLATED DERIVATIVITY THEREOF |
| JP2015502971A (ja) | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー／エス | Ｎ末端修飾インスリン誘導体 |
| KR20150002777A (ko) | 2012-04-11 | 2015-01-07 | 노보 노르디스크 에이/에스 | 인슐린 제제 |
| US20160031962A1 (en) * | 2012-04-20 | 2016-02-04 | Kleomenis K. Barlos | Solid phase peptide synthesis of insulin using side chain achored lysine |
| WO2013164375A1 (en) | 2012-05-01 | 2013-11-07 | Novo Nordisk A/S | Pharmaceutical composition |
| US20150111820A1 (en) | 2012-07-09 | 2015-04-23 | Novo Nordisk A/S | Novel use of insulin derivatives |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CN104884078B (zh) | 2012-10-17 | 2017-06-20 | 诺和诺德股份有限公司 | 用于口服肽递送的脂肪酸酰化d‑氨基酸 |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| CN105188736A (zh) * | 2013-03-20 | 2015-12-23 | 诺和诺德股份有限公司 | 胰岛素给药方案 |
| PL2986313T3 (pl) | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| AU2014333979B2 (en) | 2013-10-07 | 2018-02-15 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
| FR3013049B1 (fr) | 2013-11-14 | 2015-11-13 | You-Ping Chan | Analogue de l'insuline glargine |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| AR100306A1 (es) | 2014-02-18 | 2016-09-28 | Novo Nordisk As | Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| WO2017032795A1 (en) | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| EP3341402A1 (en) | 2015-08-25 | 2018-07-04 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| TWI747929B (zh) * | 2016-08-02 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人胰島素或其類似物的醯化衍生物 |
| MA46890A (fr) | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
| JP7193455B2 (ja) | 2016-11-28 | 2022-12-20 | ノヴォ ノルディスク アー／エス | 心血管状態におけるインスリンデグルデク |
| WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| MA49116A (fr) | 2016-12-16 | 2020-03-25 | Novo Nordisk As | Compositions pharmaceutiques contenant de l'insuline |
| JOP20190273A1 (ar) | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| MX2020007929A (es) | 2018-02-09 | 2020-10-01 | Jiangsu Hengrui Medicine Co | Gen percursor del codón optimizado y gen de péptido señal de analógo de la insulina humana. |
| EP3805257A4 (en) | 2018-05-24 | 2022-03-16 | Jiangsu Hengrui Medicine Co., Ltd. | METHOD OF PRODUCTION OF A PRECURSOR OF RECOMBINANT HUMAN INSULIN OR ANALOGUE THEREOF |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| WO2020002428A1 (en) | 2018-06-26 | 2020-01-02 | Novo Nordisk A/S | System providing dose recommendations for basal insulin titration |
| KR102666154B1 (ko) | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN118772259A (zh) | 2019-12-30 | 2024-10-15 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| CR20220641A (es) | 2020-05-15 | 2023-01-19 | Lilly Co Eli | Compuestos de insulina acilada de acción temporal prolongada |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| US20250000948A1 (en) | 2021-11-15 | 2025-01-02 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4471053A1 (en) | 2022-01-28 | 2024-12-04 | Gan & Lee Pharmaceuticals Co., Ltd. | Acylated insulin |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| US20250154220A1 (en) * | 2023-11-15 | 2025-05-15 | Ambio, Inc. | Insulin analogs for the treatment of human metabolic disorder and disease |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1212679B (de) | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Verfahren zur Herstellung von Insulinloesungen |
| GB1042194A (en) | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3868358A (en) * | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| JP3122128B2 (ja) | 1989-12-21 | 2001-01-09 | ノボ ノルディスク アクティーゼルスカブ | ペプチド製剤 |
| DK45590D0 (enExample) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| JP3193398B2 (ja) | 1991-07-23 | 2001-07-30 | サンデン株式会社 | ショ−ケ−ス |
| DE69233704T2 (de) | 1991-12-20 | 2008-05-21 | Novo Nordisk A/S | Stabilisierte pharmazeutische Formulierung, umfassend Wachstumshormon und Histidin |
| US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) * | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| SI0792290T1 (en) * | 1993-09-17 | 2001-12-31 | Novo Nordisk As | Acylated insulin |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| AU3562195A (en) | 1994-10-04 | 1996-04-26 | Novo Nordisk A/S | Preparations containing aspb28 human insulin and nicotinamide |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5830999A (en) * | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| CA2215694A1 (en) | 1995-03-17 | 1996-09-26 | Novo Nordisk A/S | Insulin derivatives |
| US6251856B1 (en) * | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5898267A (en) * | 1996-04-10 | 1999-04-27 | Mcdermott; Kevin | Parabolic axial lighting device |
| US5866538A (en) * | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5905140A (en) * | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| PT938502E (pt) | 1996-07-11 | 2005-02-28 | Novo Nordisk As | Metodo selectivo por acilacao |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| DK0821006T3 (da) * | 1996-07-26 | 2004-08-16 | Aventis Pharma Gmbh | Insulinderivater med öget zinkbinding |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| JP2001518915A (ja) | 1997-03-20 | 2001-10-16 | ノボ ノルディスク アクティーゼルスカブ | インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法 |
| EP0971729B1 (en) | 1997-03-20 | 2002-07-03 | Novo Nordisk A/S | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
| IL131796A0 (en) * | 1997-03-20 | 2001-03-19 | Novo Nordisk As | Zinc free insulin crystals for use in pulmonary compositions |
| US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| SI0884053T1 (en) | 1997-06-13 | 2003-02-28 | Eli Lilly And Company | Stable insulin formulations |
| US6451762B1 (en) * | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| ES2202899T3 (es) * | 1997-10-24 | 2004-04-01 | Novo Nordisk A/S | Agregados de derivados de la insulina humana. |
| US20020155994A1 (en) * | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
| SV1998000125A (es) | 1997-10-24 | 1999-05-24 | Lilly Co Eli | Composiciones de insulina insoluble ref. x-11232 |
| ZA989744B (en) * | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| US6531448B1 (en) | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
| EP1044016B1 (en) * | 1998-01-09 | 2005-03-16 | Novo Nordisk A/S | Stabilised insulin compositions |
| PT1121144E (pt) | 1998-10-16 | 2002-11-29 | Novo Nordisk As | Preparados de insulina concentrada estavel para administracao pulmonar |
| US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| PT2193809E (pt) * | 1999-02-22 | 2015-08-24 | Baxter Int | Formulações de fator viii livres de albumina |
| AU4450700A (en) | 1999-04-27 | 2000-11-10 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US6652886B2 (en) * | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| EP1412384B1 (en) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| BR0215029A (pt) | 2001-12-20 | 2005-12-20 | Lilly Co Eli | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus |
| AU2003208316A1 (en) * | 2002-03-13 | 2003-09-22 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| ATE496064T1 (de) * | 2002-05-07 | 2011-02-15 | Novo Nordisk As | Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten |
| US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| KR100615389B1 (ko) | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| JP2006504772A (ja) | 2002-10-29 | 2006-02-09 | アルザ・コーポレーション | 安定化された固体ポリペプチド粒子 |
| US20040138099A1 (en) * | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| RU2358738C2 (ru) | 2003-02-07 | 2009-06-20 | Адзиномото Ко., Инк. | Лекарственные средства для лечения сахарного диабета |
| DE602004027992D1 (de) | 2003-02-19 | 2010-08-19 | Novartis Ag | In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 |
| ATE485051T1 (de) | 2003-03-04 | 2010-11-15 | Technology Dev Company Ltd | Injizierbare insulinzubereitung mit langzeitwirkung und verfahren zur dessen herstellung und verwendung |
| ATE547114T1 (de) | 2003-06-25 | 2012-03-15 | Novo Nordisk Healthcare Ag | Flüssige zusammensetzungen von factor vii polypeptiden |
| US20050054818A1 (en) * | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
| KR101186851B1 (ko) | 2003-08-05 | 2012-10-02 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| WO2005016365A2 (en) | 2003-08-14 | 2005-02-24 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| WO2005021022A2 (en) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Stable formulations of peptides |
| ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
| EP1687428A1 (en) * | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| WO2005063298A1 (en) | 2003-12-23 | 2005-07-14 | Pharmacia Corporation | Stable growth hormone liquid formulation |
| EP2106790B1 (en) | 2004-03-12 | 2012-10-24 | Biodel, Inc. | Rapid acting drug delivery compositions |
| BRPI0510527A (pt) | 2004-06-01 | 2007-10-30 | Ares Trading Sa | método de estabilização de proteìnas |
| CA2576549C (en) | 2004-08-12 | 2011-01-18 | Schering Corporation | Stable pegylated interferon formulation |
| WO2006023665A2 (en) | 2004-08-17 | 2006-03-02 | Regeneron Pharmaceuticals, Inc. | Il-1 antagonist formulations |
| ES2575984T3 (es) | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal |
| JP4874989B2 (ja) | 2004-11-22 | 2012-02-15 | ノヴォ ノルディスク アー／エス | 可溶性で安定なインスリン含有調合物 |
| EP1838290A2 (en) | 2005-01-21 | 2007-10-03 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion |
| EP2256130B1 (en) * | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| DE602007009496D1 (de) * | 2006-02-27 | 2010-11-11 | Novo Nordisk As | Insulinderivate |
| CA2649109A1 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| EP2015770B1 (en) * | 2006-05-09 | 2012-09-26 | Novo Nordisk A/S | Insulin derivative |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| ES2612736T3 (es) * | 2007-11-16 | 2017-05-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
-
2004
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/ko not_active Expired - Lifetime
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/es active IP Right Grant
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/ja not_active Expired - Lifetime
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/pt active IP Right Grant
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en not_active Ceased
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
- 2004-07-22 PL PL09165072T patent/PL2107069T3/pl unknown
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
-
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/no active Protection Beyond IP Right Term
-
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/ru active
-
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
-
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
-
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/el unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/fr unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/xx unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-07-04 CY CY2013027C patent/CY2013027PI2/el unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/fr active Active
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/fr active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI1/el unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/hu unknown
-
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
-
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/no unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/no unknown
-
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/el unknown
-
2024
- 2024-01-16 NO NO2024004C patent/NO2024004I1/no unknown
- 2024-01-16 NO NO2024003C patent/NO2024003I1/no unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I2/el unknown